PHIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Phio Pharmaceuticals Corp (PHIO) is not a strong buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows mixed momentum, lacks significant trading trends, and has weak financial performance. While there are positive catalysts from clinical trial results, the stock's volatility and lack of clear technical or proprietary trading signals suggest holding off on investment at this time.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 68.582, and moving averages are converging, showing no clear trend. The stock is trading near resistance levels (R1: 1.359) but remains below its 100-day moving average, reflecting mixed momentum.
Positive Phase 1b trial results for PH-762 with an 85% pathological response rate and no serious adverse events. Plans to submit an FDA application in Q2 2026 and commence cGMP material manufacturing in the second half of 2026.
The stock remains below its 100-day moving average and experienced recent volatility. Financial performance is weak, with negative net income and declining EPS.
In 2025/Q3, revenue remained at 0 with no growth. Net income improved to -$2,392,000, up 56.96% YoY, but EPS dropped significantly to -0.44, down 71.43% YoY. Gross margin is 0, indicating no profitability.
No recent analyst ratings or price target updates are available.
